The FTA-ABS test: a diagnostic help or hindrance?

Syphilis diagnosis relies on a combination of clinical evaluation and laboratory testing. While the Venereal Disease Research Laboratory (VDRL) test is commonly used for initial screening, the fluorescent treponemal antibody absorption (FTA-ABS) test has gained attention for its high sensitivity in confirming syphilis. However, the use of FTA-ABS as a primary diagnostic tool in populations with low disease prevalence remains uncertain. Prior research has shown that confirmatory tests like FTA-ABS are more reliable when used after initial screening. This gap motivated a closer examination of FTA-ABS performance in a real-world setting. No prior work had resolved the issue of interlaboratory variability in FTA-ABS results. The study aimed to assess whether FTA-ABS could serve as a standalone diagnostic tool. It was already known that FTA-ABS is effective in detecting treponemal antibodies. However, its performance in low-prevalence settings had not been fully characterized.

The study aimed to evaluate the FTA-ABS test's reliability as an initial diagnostic tool for syphilis. Researchers tested 1,043 patients who were suspected of having the disease. The goal was to compare FTA-ABS results with those of the VDRL test, a standard initial screening method. The motivation stemmed from the increasing use of FTA-ABS in syphilis screening despite limited evidence of its effectiveness in this role. The researchers wanted to determine whether FTA-ABS could replace VDRL in low-prevalence populations. They also sought to assess the impact of laboratory procedures on test outcomes. The study focused on the consistency of FTA-ABS results across different laboratories. It was important to understand whether borderline or reactive FTA-ABS results accurately reflected syphilis status.

The study involved 1,043 patients suspected of having syphilis. Each patient underwent both VDRL and FTA-ABS testing. Sera from 226 patients with borderline or reactive results were retested in two laboratories. The local and reference laboratories used the same FTA-ABS test but followed slightly different procedures. The researchers compared the results to assess interlaboratory consistency. They also evaluated how well FTA-ABS results aligned with the clinical diagnosis of syphilis. The study design included a retrospective analysis of test outcomes. Researchers focused on the correlation between FTA-ABS results and confirmed syphilis cases.

The FTA-ABS test showed poor interlaboratory consistency for borderline or reactive results. In contrast, the VDRL test demonstrated strong consistency across both laboratories. Borderline FTA-ABS results had a weak correlation with syphilis diagnosis in both labs. A reactive FTA-ABS result correlated well only in the reference laboratory. The test's performance was affected by the low prevalence of syphilis in the study population. Minor procedural differences at the local lab further reduced test accuracy. The study found that FTA-ABS was not reliable as a standalone diagnostic tool. The results suggest that FTA-ABS should be used as a confirmatory test rather than an initial screen.

The FTA-ABS test may not be suitable as an initial screening tool for syphilis. Its performance varied significantly between laboratories. Borderline results did not reliably indicate syphilis in either lab. The test's accuracy was reduced in low-prevalence populations. Minor procedural changes at the local lab affected test outcomes. The study suggests that FTA-ABS should remain a confirmatory test. The authors propose that VDRL is more reliable for initial screening. They suggest that FTA-ABS should not replace standard screening methods in low-prevalence settings.